Emerging therapeutic targets in endometrial cancer (Q37827340)

23 August 2017

1 reference

title

Emerging therapeutic targets in endometrial cancer (English)

1 reference

23 August 2017

5

Jorge S Reis-Filho

1 reference

23 August 2017

3

Alan Ashworth

1 reference

23 August 2017

Konstantin J Dedes

1

1 reference

23 August 2017

Daniel Wetterskog

series ordinal

2

1 reference

23 August 2017

Stan B Kaye

series ordinal

4

1 reference

23 August 2017

language of work or name

English

0 references

publication date

11 January 2011

1 reference

Nature Reviews Clinical Oncology

23 August 2017

1 reference

23 August 2017

8

1 reference

23 August 2017

261-271

1 reference

23 August 2017

5

1 reference

23 August 2017

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Two pathogenetic types of endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Molecular and pathologic aspects of endometrial carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Drug-sensitive FGFR2 mutations in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Systemic therapy for recurrent endometrial cancer: a review of North American trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

The role of p16-cyclin d/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Aneuploidy predicts outcome in patients with endometrial carcinoma and is related to lack of CDH13 hypermethylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Abnormalities of E- and P-cadherin and catenin (β-, γ-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

PIK3CA mutation associates with improved outcome in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: results from studies of the NCIC Clinical Trials Group (NCIC CTG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Fibroblast growth factor signalling: from development to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Endometrial Glandular Dysplasia with Frequent p53 Gene Mutation: A Genetic Evidence Supporting Its Precancer Nature for Endometrial Serous Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Abnormalities of the APC/beta-catenin pathway in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

The multifaceted mismatch-repair system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Clinical significance of microsatellite instability in endometrial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Mismatch repair deficient colorectal cancer in the era of personalized treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Oestrogen receptor gene (ESR1) amplification is frequent in endometrial carcinoma and its precursor lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

ESR1 amplification in endometrial carcinomas: hope or hyperbole?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

mTOR signaling and drug development in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Current development of mTOR inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

The Akt-mTOR tango and its relevance to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Cancer-specific mutations in PIK3CA are oncogenic in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Determinants of rapamycin sensitivity in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Angiogenic co-operation of VEGF and stromal cell TP in endometrial carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Clinical and biological significance of vascular endothelial growth factor in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Eph receptors and ephrins in cancer: bidirectional signalling and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

EphA2 expression is associated with aggressive features in ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Induction of human endometrial cancer cell senescence through modulation of HIF-1alpha activity by EGLN1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Essential role for nuclear PTEN in maintaining chromosomal integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

The relationship between microsatellite instability and PTEN gene mutations in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Comparison of estrogen and progesterone receptor, Ki-67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Endometrioid uterine cancer: histopathological risk factors of local and distant recurrence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Uterine Neoplasms. Clinical Practice Guidelines in Oncology.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing postoperative chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Role of the p16 tumor suppressor gene in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

P16 alterations increase the metastatic potential of endometrial carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

p16INK4andp15INK4BAlterations in Primary Gynecologic Malignancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Mutational analysis of the CTNNB1 and APC genes in uterine endometrioid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Systematic review of microsatellite instability and colorectal cancer prognosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Clinicopathologic significance of DNA mismatch repair defects in endometrial cancer: the devil is in the details

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

ESR1 gene amplification in breast cancer: a common phenomenon?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Mutational analysis of the estrogen-receptor gene in endometrial carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Immunosuppressive properties of FK-506 and rapamycin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Prognostic value of epidermal growth factor receptor expression in endometrioid endometrial carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Significance of epidermal growth factor receptor expression in primary human endometrial cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Use of trastuzumab in the treatment of metastatic endometrial cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Vascular proliferation is important for clinical progress of endometrial cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Increased expression of hypoxia-inducible factor 1alpha in type I and type II endometrial carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.216

Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium

31 March 2020

1 reference

12 December 2020

Mismatch repair genes and microsatellite instability as molecular markers for gynecological cancer detection

1 reference

12 December 2020

E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium

1 reference

12 December 2020

Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer.

1 reference

12 December 2020

PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics.

1 reference

12 December 2020

Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer.

1 reference

12 December 2020

Beta-catenin mutation in carcinoma of the uterine endometrium

1 reference

12 December 2020

Frequency and prognostic impact of microsatellite instability in a large population-based study of endometrial carcinomas

1 reference

12 December 2020

Insights into endometrial serous carcinogenesis and progression

1 reference

12 December 2020

Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix

1 reference

12 December 2020

Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis.

1 reference

12 December 2020

10.1038/NRCLINONC.2010.216

Identifiers

DOI

1 reference

OpenCitations bibliographic resource ID

23 August 2017

0 references

1 reference